Skip to content
Community, Medical Health Aged Care

Accessible healthcare win for Australians affected by mitochondrial disease

NeuRA 2 mins read
Professor Carolyn Sue at the Neuroscience Research Australia labs.

For the first time, publicly funded genetic testing is now readily available for Australians who suspect they have mitochondrial disease, enabling them to receive accurate diagnoses and timely treatments.

The Department of Health and Aged Care’s Medical Services Advisory Committee (MSAC) granted approval for whole genome sequencing (genetic testing) in diagnosing primary mitochondrial disease and the changes came into effect this month. 

“This approval marks a turning point, especially for patients and families, many of whom spend decades trying to get a definitive diagnosis of this condition,” says Professor Carolyn Sue AM, an internationally recognised clinician-scientist here at Neuroscience Research Australia and leader in Parkinson’s and mitochondrial disease.

“I’m proud to have led this work with distinguished researchers and professionals in the field of mitochondrial research and advocacy to secure this achievement.”

How will this impact the lives of Australians affected by mitochondrial disease?

In the past, genetic testing for mitochondrial diseases has been a rare and costly option, accessible mainly through research funding, or presenting families with substantial out-of-pocket expenses, often amounting to over $4,000. But this is no longer the case as starting from this month, the test is now covered by Medicare. 

“Publicly funded genetic testing means patients no longer have to face years of uncertainty, seeing an average of 5 – 8 doctors before receiving a diagnosis. Now a simple blood test will enable individuals to get a diagnosis,” says Professor Sue.

“Accessible genetic screening will also shorten diagnosis time for individuals and help them make informed decisions about family planning.

“This will allow them to consider reproductive options like mitochondrial donation through IVF to prevent transmitting the disease to their biological children.

“Importantly, all patients, regardless of their age or life circumstances, will be able to get the right treatments promptly, preventing disease progression and avoiding potentially harmful treatments, a common risk due to the variable nature of mitochondrial disease symptoms.”

A decade dedicated to advocacy

Securing genetic testing for mitochondrial diseases was an achievement that is the result of a decade-long collaborative effort between researchers and mitochondrial advocates.

Involved in the submission process were Professor Carolyn Sue AM, Kinghorn Chair, Neurodegeneration at Neuroscience Research Australia, alongside the Mito Medical Network and researchers from the Centre for Economic Impacts of Genomic Medicine at Macquarie University, and The Children’s Hospital at Westmead.

What is mitochondrial disease?

Mitochondrial diseases, often described as conditions that ​“rob the body of energy,” stem from genetic variations affecting the mitochondria’s ability to create energy. 

Genetic variants that can cause mitochondrial disease are surprisingly common, impacting approximately one in 200 people in Australia. The symptoms of mitochondrial disease are diverse, ranging from extreme fatigue and strokes to seizures, diabetes, and severe hearing loss. 

Key Facts:

Professor Carolyn Sue is available for media interviews.

Previous example of an interview available here: 

About us:

About NeuRA:
From advances in dementia and mental health to discoveries in chronic pain and falls prevention, Neuroscience Research Australia (NeuRA) has been at the forefront of neuroscience for over 30 years. We are an independent, not-for-profit, medical research institute dedicated to improving the lives of people living with brain and nervous system disorders.

Contact details:

Nadia Razzhigaeva

Senior Communications & PR Officer

0452 140 477


More from this category

  • Medical Health Aged Care
  • 20/04/2024
  • 04:30
Dementia Australia

Join us TODAY for Bendigo Memory Walk & Jog

What: Dementia Australia’sBendigoMemory Walk & Jog When: Saturday 20 April, from 8am Who: More than 390 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Where: Bendigo Botanic Gardens, Bendigo For more information visit: Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people…

  • Contains:
  • Medical Health Aged Care, Science
  • 19/04/2024
  • 15:00
Monash University

Large-scale genetic study finds new link between Irritable Bowel Syndrome and the cardiovascular system

New research published today in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD). Led by Dr Leticia Camargo Tavares, a Postdoctoral Fellow at the Hypertension Research Laboratory within Monash University’s School of Biological Sciences, the study reveals novel insights into the genetic underpinnings of IBS, offering potential avenues for therapeutic intervention. IBS is one of the most prevalent gastrointestinal disorders globally, affecting up to 10 per cent of the population, with a disproportionate impact on women. It is characterised by a complex range of symptoms…

  • Community, Political
  • 19/04/2024
  • 14:00
Flying Elephant Media; Media contact 0413 050 922;

Australia Stands for Peace

Australia Stands for Peace Australia erupts into demonstrations and violence about an overseas war, on our Opera House steps, at the Christmas Carols in…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.